ALXN has been the subject of several other reports. Jefferies Group lowered their target price on shares of Alexion Pharmaceuticals from $140.00 to $120.00 and set a hold rating for the company in a research note on Friday, September 23rd. Leerink Swann raised their target price on shares of Alexion Pharmaceuticals from $210.00 to $211.00 and gave the company an outperform rating in a research note on Monday, September 26th. Vetr raised shares of Alexion Pharmaceuticals from a buy rating to a strong-buy rating and set a $146.84 price target for the company in a report on Thursday, August 25th. Citigroup Inc. raised their price target on shares of Alexion Pharmaceuticals from $154.00 to $155.00 and gave the stock a buy rating in a report on Tuesday, September 20th. Finally, Zacks Investment Research raised shares of Alexion Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, September 27th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $178.32.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 1.23% during midday trading on Friday, hitting $126.59. 276,433 shares of the stock were exchanged. Alexion Pharmaceuticals has a 12 month low of $110.56 and a 12 month high of $193.45. The stock has a market cap of $28.39 billion, a price-to-earnings ratio of 318.07 and a beta of 1.33. The firm’s 50-day moving average is $127.74 and its 200-day moving average is $134.87.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.17 by $0.04. The firm earned $753 million during the quarter, compared to analyst estimates of $743.18 million. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. Alexion Pharmaceuticals’s revenue was up 18.4% on a year-over-year basis. During the same quarter last year, the business earned $1.44 earnings per share. Equities research analysts predict that Alexion Pharmaceuticals will post $4.67 earnings per share for the current year.
In other Alexion Pharmaceuticals news, EVP Carsten Thiel sold 1,000 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $125.94, for a total transaction of $125,940.00. Following the transaction, the executive vice president now directly owns 40,579 shares of the company’s stock, valued at $5,110,519.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David Hallal sold 332 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $137.14, for a total transaction of $45,530.48. Following the transaction, the chief executive officer now directly owns 189,266 shares in the company, valued at $25,955,939.24. The disclosure for this sale can be found here. Company insiders own 4.41% of the company’s stock.
Institutional investors have recently modified their holdings of the company. Glenmede Trust Co. NA increased its position in shares of Alexion Pharmaceuticals by 38.1% in the first quarter. Glenmede Trust Co. NA now owns 3,077 shares of the biopharmaceutical company’s stock worth $427,000 after buying an additional 849 shares during the period. Virginia Retirement System purchased a new position in shares of Alexion Pharmaceuticals during the first quarter worth approximately $509,000. Nikko Asset Management Americas Inc. purchased a new position in shares of Alexion Pharmaceuticals during the first quarter worth approximately $297,000. NN Investment Partners Holdings N.V. purchased a new position in shares of Alexion Pharmaceuticals during the first quarter worth approximately $9,685,000. Finally, TimesSquare Capital Management LLC increased its position in shares of Alexion Pharmaceuticals by 430.2% in the first quarter. TimesSquare Capital Management LLC now owns 39,555 shares of the biopharmaceutical company’s stock worth $5,507,000 after buying an additional 32,095 shares during the period. 96.34% of the stock is currently owned by institutional investors.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.